Under a tenth of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its first guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging increased and just availability to GLP-1 medication.
According to estimates, over two billion will be obese by 2030 unless action is taken.
"The new guidelines affirms that obesity is a long-term condition that can be managed with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant barriers to universal access to the jabs that can help people shift considerable body mass, says the organization.
GLP-1 Therapy Shortage
Even in the present most optimistic outlook, the manufacturing of such drugs might only reach around 100 million people – under 10% of eligible patients, per the health organization.
The recommendation calls on nations and manufacturers to expand access, by approaches such as voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Injections Operate
The injections imitate a biological compound to slow digestion, curb appetite and enhance the sense of being full so people reduce food intake.
People typically see weight reduction in the initial weeks of beginning the regular doses.
Evidence points to patients may see weight return after a year of halting the medication, because their typical hunger come back.
Being carrying excess weight increases your chance for developing diseases, like type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
